Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Hanmi Pharmaceuticals (Diabetes Drug Licence)

Hanmi Pharmaceuticals (Diabetes Drug Licence)
M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A license to develop and commercialize a portfolio of experimental pharmaceuticals for the treatment of diabetes. The portfolio encompasses: efpeglenatide, a late-stage long-acting glucagon-like peptide-1 receptor agonists (GLP1-RA); a weekly insulin; and a fixed-dosed weekly GLP-1-RA/insulin drug combination. Collectively, these therapeutic offerings are known as the "Quantum Project" utilizing Hanmi's proprietary Long Acting Protein / Peptide Discovery Platform LAPSCOVERY technology.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 14, Wiryeseong-daero
  • Songpa-gu
  • Seoul, 05545
  • South Korea

Hanmi Pharmaceuticals (Diabetes Drug Licence) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Hanmi Pharmaceuticals (Diabetes Drug Licence)‘s full profile, request access.

Request full access to PitchBook

Hanmi Pharmaceuticals (Diabetes Drug Licence) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Hanmi Pharmaceuticals (Diabetes Drug Licence)‘s full profile, request access.

Request full access to PitchBook